Understanding cancer risk in patients at lower risk to improve early cancer diagnosis.

Lancet Oncol

Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.

Published: November 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(23)00514-4DOI Listing

Publication Analysis

Top Keywords

understanding cancer
4
cancer risk
4
risk patients
4
patients lower
4
lower risk
4
risk improve
4
improve early
4
early cancer
4
cancer diagnosis
4
risk
2

Similar Publications

Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLC pathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis.

View Article and Find Full Text PDF

Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications.

View Article and Find Full Text PDF

CD163, a macrophage-specific receptor, plays a critical role in scavenging hemoglobin released during hemolysis, protecting against oxidative effects of heme iron. In the bloodstream, hemoglobin is bound by haptoglobin, leading to its immediate endocytosis by CD163. While haptoglobin's structure and function are well understood, CD163's structure and its interaction with the haptoglobin-hemoglobin complex have remained elusive.

View Article and Find Full Text PDF

Investigation of the impact of R273H and R273C mutations on the DNA binding domain of P53 protein through molecular dynamic simulation.

J Biomol Struct Dyn

February 2025

Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, India.

The P53 protein, a cancer-associated transcriptional factor and tumor suppressor, houses a Zn ion in its DNA-binding domain (DBD), essential for sequence-specific DNA binding. However, common mutations at position 273, specifically from Arginine to Histidine and Cysteine, lead to a loss of function as a tumor suppressor, also called DNA contact mutations. The mutant (MT) P53 structure cannot stabilize DNA due to inadequate interaction.

View Article and Find Full Text PDF

Rethinking BCC diagnosis: Automating concept-specific detection of BCC in dermatoscopic images.

J Dtsch Dermatol Ges

December 2024

Department of Dermatology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.

Background: Basal cell carcinoma (BCC) is a prevalent type of skin cancer in which the inherent subjectivity of dermoscopy poses diagnostic challenges. Existing AI systems, which provide mainly image-level insights, lack the interpretability that is crucial for effective clinical decisions and patient education.

Patients And Methods: Our study developed a refined BCC dataset from the Human‒Machine Adversarial Model (HAM10000), which was annotated by clinicians to identify key diagnostic features.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!